Financings Of The Fortnight And The Never-Ending Venture Round
This article was originally published in The Pink Sheet Daily
Executive Summary
While not as high-profile as some other venture raises over the last year, Novimmune has pulled in CHF 200.5 million in Series B financing over 16 years. Plus, news on raises by Pronutria, Melinta, Argos and Arrowhead.
You may also be interested in...
Humabs BioMed Seeking Clinical Development Partner For ‘Natural Selection’ MAbs
Novartis and MedImmune have over the past several months also started clinical studies of antibodies licensed from the Swiss biotech, which derives its products from patients with highly effective immune responses.
Rivalry Intensifies In Europe For Biotech Funding, Product Development
U.K. biotech companies lead Europe in terms of funds raised and products in development in the first half of 2014, but other countries in the region are not far behind.
Does Alnylam Lift All Oligo Boats? The Dicerna IPO
Dicerna’s debut stood out even in a hot market for biotech IPOs, but it is hard to sort out how much investor enthusiasm was driven by its specific technologies, rub-off from the recent Alnylam/ Sanofi-Genzyme deal, and demands of insiders who wanted liquidity but not dilution.